We have received a community statement about Roche’s support for people affected by the war in Ukraine.
Roche has initiated a global support programme to ensure uninterrupted access to treatment for all people in or from Ukraine who are currently receiving risdiplam. This includes those receiving risdiplam through clinical trials, the Pre-Approval Access/Compassionate Use Programme or other commercial pathways (i.e., out of pocket purchase or state funded programme in Ukraine).
Maintaining risdiplam supply
The primary focus is to ensure continued supply of risdiplam within the scope of the available possibilities. While borders are not officially closed, it is extremely difficult to get any shipments into the country. Currently Roche has sufficient product supply in Ukraine but is hindered by the severe destruction of local infrastructure and disruption to logistics and supply chain channels. Roche is making every effort to ensure their medicines reach centres that remain able to provide care and is seeking alternative means of distribution for individuals where this is not the case.
The supply and delivery of medicines and diagnostics are currently exempted from sanctions. Roche is doing everything it can to maintain supply and delivery within the scope of the available possibilities.
For more information click on the links below: